Ranitidine

Explore a selection of our essential drug information below, or:

CREATE FREE ACCOUNT

Full Drug Profiles

Unlock enhanced features & extensive drug insights, including detailed interaction data & regulatory status. Create a free account.

SUBSCRIBERECOMMENDED FOR PHARMA

Data Packages

Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Identification

Summary

Ranitidine is a histamine H2 antagonist used to treat duodenal ulcers, Zollinger-Ellison syndrome, gastric ulcers, GERD, and erosive esophagitis.

Brand Names

Good Sense Acid Reducer, Wal-zan, Zantac

Generic Name

Ranitidine

DrugBank Accession Number

DB00863

Background

Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as cimetidine and famotidine. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.^2,11 Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.^11,14

The prevalence of GERD is thought to be 10-20% in western countries.⁴ Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.^5,11

Type

Small Molecule

Groups

Approved, Withdrawn

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for Ranitidine (DB00863)

×

Close

Weight

Average: 314.4
Monoisotopic: 314.141261758

Chemical Formula

C₁₃H₂₂N₄O₃S

Synonyms

• Ranitidina
• Ranitidine
• Ranitidinum

Unlock the secrets to drugging the undruggable

Discover how groundbreaking research is turning "undruggable" targets into therapeutic opportunities.

Download eBook

Unlock the secrets to drugging the undruggable

Download eBook

Pharmacology

Indication

This drug is used alone or with concomitant antacids for the following conditions: short-term treatment of active duodenal ulcer, treating gastric acid hypersecretion due to Zollinger-Ellison syndrome, systemic mastocytosis, and other conditions that may pathologically raise gastric acid levels. It also used in the short term treatment of active benign gastric ulcers and maintenance therapy of gastric ulcers at a reduced dose. In addition to the above, ranitidine can be used for the treatment of GERD symptoms, treatment of erosive esophagitis (endoscopically diagnosed) and the maintenance of gastric or duodenal ulcer healing.^11,12

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Age Group	Patient Characteristics	Dose Form
Prophylaxis of	Acid aspiration syndrome		••••••••••••			•••••••••• ••••••
Used in combination for symptomatic treatment of	Ankylosing spondylitis	Regimen in combination with: Capsicum oleoresin (DB11131), Diclofenac (DB00586)	••••••••••••
Prophylaxis of	Duodenal ulcer		••••••••••••			•••••••••• ••••••
Treatment of	Duodenal ulcer		••••••••••••			•••••••••
Used in combination to treat	Erosive esophagitis	Regimen in combination with: Magnesium carbonate (DB09481), Aluminum hydroxide (DB06723), Calcium carbonate (DB06724), Almasilate (DB13595), Sodium bicarbonate (DB01390), Aluminium phosphate (DB14517), Magnesium trisilicate (DB09281), Magnesium hydroxide (DB09104), Magnesium oxide (DB01377), Magaldrate (DB08938), Aluminium (DB01370)	••••••••••••

Create Account

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Ranitidine decreases the secretion of gastric acid stimulated by food and drugs. It also reduces the secretion of gastric acid in hypersecretory conditions such as Zollinger-Ellison syndrome.^6,11 Marked improvements in the appearance of the esophageal tissues have been observed by endoscopic imaging after ranitidine therapy.^5,11

Mechanism of action

After a meal, the hormone gastrin, produced by cells in the lining of the stomach, stimulates the release of histamine, which then binds to histamine H2 receptors, leading to the secretion of gastric acid. Ranitidine reduces the secretion of gastric acid by reversible binding to histamine (H2) receptors, which are found on gastric parietal cells. This process leads to the inhibition of histamine binding to this receptor, causing the reduction of gastric acid secretion. The relief of gastric-acid related symptoms can occur as soon as 60 minutes after administration of a single dose, and the effects can last from 4-10 hours, providing fast and effective symptomatic relief.^3,9,11

Target	Actions	Organism
AHistamine H2 receptor	antagonist	Humans
UAcetylcholinesterase	inhibitor	Humans

Absorption

Ranitidine is rapidly absorbed with peak concentrations reached within 1-3 hours after administration, and varying greatly among patients. Bioavailability is about 50%-60% due to hepatic metabolism.^7,13 In a pharmacokinetic study of healthy males, the AUC 0-infinity was about 2,488.6 ng x h/mL and the median Tmax was 2.83 hours.⁸ Food or antacids have limited effects on absorption. One clinical study found that the administration of a potent antacid (150 mmol) in subjects in the fasted state led to decreased absorption of ranitidine.¹¹

Volume of distribution

The volume of distribution is higher than body volume, and measures at approximately 1.4 L/kg.^7,11 It concentrates in breast milk, but does not readily distribute into the cerebrospinal fluid.⁷

Protein binding

The plasma protein binding of ranitidine is approximately 15%.^7,11

Metabolism

The major metabolite in the urine is N-oxide, which represents less than 4% of the dose. Other metabolites of ranitidine include S-oxide (1%) and desmethyl ranitidine (1%).^11,13 The feces contain the remainder of the excreted ranitidine dose. Liver dysfunction has been shown to cause small, but clinically insignificant, changes in various ranitidine pharmacokinetic parameters.¹¹

Hover over products below to view reaction partners

• Ranitidine
  • Desmethylranitidine
  • Ranitidine N-Oxide
  • Ranitidine S-Oxide

Route of elimination

This drug is mainly excreted in the urine but also excreted in the feces.^7,13 About 30% of a single oral dose has been measured in the urine as unchanged drug within 24 hours of ingestion.¹¹

Half-life

The elimination half-life or ranitidine is about 2.5-3 hours.^7,11 It may be longer after oral administration versus injection.⁷ The plasma half-life is longer for elderly patients population due to a decrease in renal function, and is measured at 3-4 hours.^7,11

Clearance

Renal clearance is about 410 mL/min according to FDA prescribing information.¹¹ Another resource mentions a plasma clearance of approximately 600 ml/min.⁷ Clearance is decreased in the elderly and those with impaired or hepatic renal function.^7,11 It is recommended to decrease the dose of ranitidine by one-half in patients with renal impairment.¹¹

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Oral doses of 1,000 mg/kg in mice and rats were not found to be lethal. Intravenous LD50 values in mice and rats were 77 and 83 mg/kg, respectively.¹²

Overdose information

There has been limited experience with ranitidine overdose. Reported acute ingestions of up to 18 grams orally were followed by temporary adverse effects similar to the normal adverse effects of this drug, including tachycardia, bradycardia, dizziness, diarrhea, nausea, and vomiting, among other effects.¹² Gait abnormalities and hypotension have also been observed. When an overdose with ranitidine is suspected, remove unabsorbed ranitidine from the gastrointestinal tract if possible, and monitor the patient and provide supportive therapy as required.^11,13

Pathways

Pathway	Category
Ranitidine Action Pathway	Drug action

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Abacavir	Ranitidine may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abametapir	The serum concentration of Ranitidine can be increased when it is combined with Abametapir.
Abatacept	The metabolism of Ranitidine can be increased when combined with Abatacept.
Abiraterone	The serum concentration of Ranitidine can be increased when it is combined with Abiraterone.
Acamprosate	The excretion of Acamprosate can be decreased when combined with Ranitidine.

Food Interactions

• Take with or without food. The absorption is unaffected by food.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Ranitidine bismuth citrate	7AJ51I17KG	128345-62-0	XAUTYMZTJWXZHZ-UHFFFAOYSA-K
Ranitidine hydrochloride	BK76465IHM	66357-59-3	GGWBHVILAJZWKJ-UHFFFAOYSA-N

Product Images

PreviousNext

International/Other Brands

Alquen / Gastrolav / Gastrosedol / Kuracid / Ptinolin / Raniberl / Ranicux / Ranidil / Ranidin / Ranidine / Ranidura / Ranigast / Raniplex / Ranisan / Ranitab / Ranitic / Ranitidin / Ranitin / Ranitine / Ranobel / Rantacid / Ranuber / Renatac / Sostril / Tanidina / Toriol / Ulcodin / Zandid / Zantic

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Acid Reducer	Tablet	150 mg	Oral	Pendopharm Division Of Pharmascience Inc	Not applicable	Not applicable
Act Ranitidine	Tablet	150 mg	Oral	Teva Italia S.R.L.	2004-04-19	2020-08-17
Act Ranitidine	Tablet	300 mg	Oral	Teva Italia S.R.L.	2004-02-19	2020-08-17
Bci Ranitidine	Tablet	300 mg	Oral	Baker Cummins Inc	Not applicable	Not applicable
Bci Ranitidine	Tablet	150 mg	Oral	Baker Cummins Inc	Not applicable	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Ag-ranitidine	Tablet	300 mg	Oral	Angita Pharma Inc.	Not applicable	Not applicable
Ag-ranitidine	Tablet	150 mg	Oral	Angita Pharma Inc.	2019-08-14	2021-12-03
Apo-ranitidine	Solution	75 mg / 5 mL	Oral	Apotex Corporation	2006-07-14	Not applicable
Apo-ranitidine Tablet 150mg	Tablet	150 mg	Oral	Apotex Corporation	1987-12-31	Not applicable
Apo-ranitidine Tablet 300mg	Tablet	300 mg	Oral	Apotex Corporation	1987-12-31	Not applicable

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
7 Select Acid Reducer	Tablet, film coated	150 mg/1	Oral	7-Eleven	2014-04-22	2020-11-30
Acid Reducer	Tablet	150 mg/1	Oral	Cardinal Health	2013-09-25	Not applicable
Acid Reducer	Tablet, film coated	150 mg/1	Oral	Shopko Stores Operating	2013-06-05	Not applicable
Acid Reducer	Tablet	75 mg	Oral	Mylan Pharmaceuticals Inc.	1998-06-25	2016-11-02
Acid Reducer	Tablet	75 mg/1	Oral	Medicine Shoppe International	2009-06-11	2012-03-01

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
DeramsilkRx Anodynexa Pak	Ranitidine hydrochloride (150 mg/1) + Capsicum oleoresin (0.25 mg/1mL) + Diclofenac sodium (75 mg/1)	Kit	Oral; Topical	Patchwerx Labs	2015-06-12	Not applicable
DermacinRx Inflammatral Pak	Ranitidine hydrochloride (150 mg/1) + Capsicum oleoresin (0.25 mg/1mL) + Diclofenac sodium (75 mg/1)	Kit	Oral; Topical	PureTek Corporation	2015-06-12	2019-03-05
Inflammation Reduction Pack	Ranitidine hydrochloride (150 mg/1) + Diclofenac sodium (75 mg/1) + Lidocaine (25 mg/1g) + Prilocaine (25 mg/1g)	Kit	Oral; Topical	Tmig, Inc.	2015-08-18	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Deprizine	Ranitidine hydrochloride (6.4 g/6.4g)	Kit	Oral	California Pharmaceuticals, Llc	2016-01-01	2018-01-05
Deprizine	Ranitidine hydrochloride (4.2 g/4.2g)	Kit	Oral	Fusion Pharmaceuticals LLC	2010-02-08	2014-08-01
Gabitidine	Ranitidine hydrochloride (150 mg/1) + Choline (125 mg/1)	Kit	Oral	Physician Therapeutics Llc	2011-07-07	Not applicable
Ranitidine Hydrochloride Oral Suspension Kit	Ranitidine hydrochloride (6.4 g/6.4g)	Kit	Oral	California Pharmaceuticals, Llc	2017-01-02	Not applicable
Sentradine	Ranitidine hydrochloride (150 mg/1) + Choline (250 mg/1)	Kit	Oral	Physician Therapeutics Llc	2011-07-07	Not applicable

Categories

ATC Codes

A02BA07 — Ranitidine bismuth citrate

• A02BA — H2-receptor antagonists
• A02B — DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
• A02 — DRUGS FOR ACID RELATED DISORDERS
• A — ALIMENTARY TRACT AND METABOLISM

A02BA02 — Ranitidine

• A02BA — H2-receptor antagonists
• A02B — DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
• A02 — DRUGS FOR ACID RELATED DISORDERS
• A — ALIMENTARY TRACT AND METABOLISM

Drug Categories

• Acid Reducers
• Agents Causing Muscle Toxicity
• Alimentary Tract and Metabolism
• Anti-Ulcer Agents
• Cholinesterase Inhibitors
• Cytochrome P-450 CYP1A2 Inhibitors
• Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)
• Cytochrome P-450 CYP1A2 Substrates
• Cytochrome P-450 CYP2D6 Inhibitors
• Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)
• Cytochrome P-450 CYP3A Inhibitors
• Cytochrome P-450 CYP3A4 Inhibitors
• Cytochrome P-450 CYP3A4 Inhibitors (weak)
• Cytochrome P-450 Enzyme Inhibitors
• Cytochrome P-450 Substrates
• Drugs for Acid Related Disorders
• Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
• Drugs that are Mainly Renally Excreted
• Furans
• Gastric Acid Lowering Agents
• Gastrointestinal Agents
• Histamine Antagonists
• Histamine H2 Antagonists
• OAT1/SLC22A6 inhibitors
• OAT1/SLC22A6 Substrates
• OAT3/SLC22A8 Substrates
• OCT1 inhibitors
• OCT1 substrates
• OCT2 Inhibitors
• OCT2 Substrates
• P-glycoprotein inhibitors
• P-glycoprotein substrates

Classification

Not classified

Affected organisms

• Humans and other mammals

Chemical Identifiers

UNII

884KT10YB7

CAS number

66357-35-5

InChI Key

VMXUWOKSQNHOCA-UHFFFAOYSA-N

InChI

InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3

IUPAC Name

[1-({2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}amino)-2-nitroethenyl](methyl)amine

SMILES

CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O

References

Synthesis Reference

John W. Clitherow, "Intermediates in the preparation of ranitidine." U.S. Patent US4413135, issued November, 1981.

US4413135

General References

1. Mauran A, Goze T, Abadie D, Bondon-Guitton E, Chevrel P, Schmitt L, Montastruc JL, Montastruc F: Mania associated with ranitidine: a case report and review of literature. Fundam Clin Pharmacol. 2016 Aug;30(4):294-6. doi: 10.1111/fcp.12201. Epub 2016 May 5. [Article]
2. Grant SM, Langtry HD, Brogden RN: Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1989 Jun;37(6):801-70. doi: 10.2165/00003495-198937060-00003. [Article]
3. Pettit M: Treatment of gastroesophageal reflux disease. Pharm World Sci. 2005 Dec;27(6):432-5. doi: 10.1007/s11096-005-4798-7. [Article]
4. Badillo R, Francis D: Diagnosis and treatment of gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther. 2014 Aug 6;5(3):105-12. doi: 10.4292/wjgpt.v5.i3.105. [Article]
5. Sontag S, Robinson M, McCallum RW, Barwick KW, Nardi R: Ranitidine therapy for gastroesophageal reflux disease. Results of a large double-blind trial. Arch Intern Med. 1987 Aug;147(8):1485-91. [Article]
6. Vezzadini P, Bonora G, Tomassetti P, Pazzaglia M, Labo G: Medical treatment of Zollinger-Ellison syndrome with ranitidine. Int J Tissue React. 1983;5(4):339-43. [Article]
7. Roberts CJ: Clinical pharmacokinetics of ranitidine. Clin Pharmacokinet. 1984 May-Jun;9(3):211-21. doi: 10.2165/00003088-198409030-00003. [Article]
8. Gschwend MH, Guserle R, Erenmemisoglu A, Martin W, Tamur U, Kanzik I, Hincal AA: Pharmacokinetics and bioequivalence study of ranitidine film tablets in healthy male subjects. Arzneimittelforschung. 2007;57(6):315-9. doi: 10.1055/s-0031-1296625. [Article]
9. Caitlin C. Nugent; Jamie M. Terrell (2018). H2 Blockers- StatPearls. StatPearls Publishing.
10. FDA drug approval package: Zantac [Link]
11. FDA Approved Drug Products: ZANTAC (ranitidine hydrochloride) injection [Link]
12. GlaxoSmithKline Canada Inc. Product Monograph: Zantac (ranitidine) [Link]
13. Ranitidine product monograph [Link]
14. Zantac injection FDA label [File]
15. Zantac Canadian Monograph [File]

External Links

Human Metabolome Database

HMDB0259516

KEGG Drug

D00422

PubChem Compound

3001055

PubChem Substance

46505543

ChemSpider

4863

BindingDB

50103506

RxNav

9143

ChEBI

92246

ChEMBL

CHEMBL1790041

Therapeutic Targets Database

DAP000340

PharmGKB

PA451224

Guide to Pharmacology

GtP Drug Page

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

Wikipedia

Ranitidine

FDA label

Download (1.03 MB)

MSDS

Download (73.9 KB)

Clinical Trials

Clinical Trials

Clinical Trial & Rare Diseases Add-on Data Package

Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package

Phase	Status	Purpose	Conditions	Count	Start Date	Why Stopped	100+ additional columns
Unlock 175K+ rows when you subscribe.View sample data
Not Available	Completed	Not Available	Community Acquired Pneumonia (CAP) / Gastro-esophageal Reflux Disease (GERD)	1	somestatus	stop reason	just information to hide
Not Available	Completed	Not Available	GnRH Trigger and Rescue Protocol	1	somestatus	stop reason	just information to hide
Not Available	Completed	Not Available	Infertility	1	somestatus	stop reason	just information to hide
Not Available	Completed	Not Available	Pharmacokinetics / Voriconazole	1	somestatus	stop reason	just information to hide
Not Available	Completed	Not Available	Stroke	1	somestatus	stop reason	just information to hide

Unlock 75,000+ rows when you subscribe

Explore data packages curated & structured to speed up your pharmaceutical research

View Sample Data

Pharmacoeconomics

Manufacturers

• Dr reddys laboratories ltd
• Genpharm inc
• Sandoz inc
• Teva pharmaceuticals usa inc
• Glaxosmithkline
• Bedford laboratories div ben venue laboratories inc
• Ben venue laboratories inc
• Alpharma us pharmaceuticals division
• Amneal pharmaceuticals
• Apotex inc
• Aurobindo pharma usa inc
• Cypress pharmaceutical inc
• Pharmaceutical assoc inc div beach products
• Ranbaxy laboratories ltd
• Vintage pharmaceuticals inc
• Wockhardt ltd
• Boehringer ingelheim pharmaceuticals inc
• Amneal pharmaceuticals ny llc
• Boehringer ingelheim corp
• Contract pharmacal corp
• Dr reddys laboratories inc
• Glenmark generics inc usa
• Ivax pharmaceuticals inc sub teva pharmaceuticals usa
• Mylan pharmaceuticals inc
• Par pharmaceutical inc
• L perrigo co
• Ranbaxy pharmaceuticals inc
• Torpharm inc
• Watson laboratories inc
• Wockhardt americas inc
• Boehringer ingelheim

Packagers

• Actavis Group
• Advanced Pharmaceutical Services Inc.
• Aidarex Pharmacuticals LLC
• Amerisource Health Services Corp.
• Amneal Pharmaceuticals
• Apotex Inc.
• Apotheca Inc.
• Apothecon
• AQ Pharmaceuticals Inc.
• A-S Medication Solutions LLC
• Banner Pharmacaps Inc.
• Bedford Labs
• Ben Venue Laboratories Inc.
• Blenheim Pharmacal
• Boehringer Ingelheim Ltd.
• Bryant Ranch Prepack
• Cardinal Health
• Central Texas Community Health Centers
• Chain Drug
• Cobalt Pharmaceuticals Inc.
• Comprehensive Consultant Services Inc.
• Corepharma LLC
• Coupler Enterprises Inc.
• CVS Pharmacy
• Dept Health Central Pharmacy
• DHHS Program Support Center Supply Service Center
• Direct Dispensing Inc.
• Dispensing Solutions
• Diversified Healthcare Services Inc.
• Doctor Reddys Laboratories Ltd.
• DSM Corp.
• Fusion Pharmaceuticals LLC
• Genpharm LP
• GlaxoSmithKline Inc.
• Glenmark Generics Ltd.
• Golden State Medical Supply Inc.
• H.J. Harkins Co. Inc.
• Heartland Repack Services LLC
• Hospira Inc.
• Innovative Manufacturing and Distribution Services Inc.
• Innoviant Pharmacy Inc.
• Ivax Pharmaceuticals
• Kaiser Foundation Hospital
• Keltman Pharmaceuticals Inc.
• Lake Erie Medical and Surgical Supply
• Liberty Pharmaceuticals
• Major Pharmaceuticals
• Mckesson Corp.
• Medisca Inc.
• Medvantx Inc.
• Murfreesboro Pharmaceutical Nursing Supply
• Mylan
• Novopharm Ltd.
• Nucare Pharmaceuticals Inc.
• Ohm Laboratories Inc.
• Palmetto Pharmaceuticals Inc.
• Par Pharmaceuticals
• Patheon Inc.
• PCA LLC
• PD-Rx Pharmaceuticals Inc.
• Penn Labs
• Perrigo Co.
• Pharmaceutical Association
• Pharmaceutical Packaging Center
• Pharmedix
• Physicians Total Care Inc.
• Precision Dose Inc.
• Preferred Pharmaceuticals Inc.
• Prepackage Specialists
• Prepak Systems Inc.
• Prescription Dispensing Service Inc.
• Prx Pharmaceuticals
• Ranbaxy Laboratories
• Rebel Distributors Corp.
• Redpharm Drug
• Remedy Repack
• Resource Optimization and Innovation LLC
• Roxane Labs
• Sandhills Packaging Inc.
• Sandoz
• Shasun Chemicals & Drugs Ltd.
• Southwood Pharmaceuticals
• St Mary's Medical Park Pharmacy
• Sunmark
• Teva Pharmaceutical Industries Ltd.
• Torpharm Inc.
• Tya Pharmaceuticals
• UDL Laboratories
• Va Cmop Dallas
• Vangard Labs Inc.
• Vistapharm Inc.
• Walgreen Co.
• Watson Pharmaceuticals
• Wockhardt Ltd.
• Xactdose Inc.

Dosage Forms

Form	Route	Strength
Tablet	Oral	75 mg / tab
Tablet	Oral	75.0 mg / tab
Tablet	Oral	300.000 mg
Solution	Intravenous	56.45 mg
Tablet	Oral	150.000 mg
Injection, solution		25 mg/mL
Tablet, film coated	Oral	400 mg
Kit	Oral	4.2 g/4.2g
Kit	Oral	6.4 g/6.4g
Kit	Oral; Topical
Tablet, effervescent	Oral	150 MG
Tablet, effervescent	Oral	300 MG
Tablet	Oral	75 mg/1
Tablet, film coated	Oral	150.00 mg
Tablet, effervescent	Oral	75 MG
Injection	Intramuscular; Intravenous	50 mg/2ml
Suspension	Oral	3500.000 mg
Solution	Oral	4.000 g
Syrup	Oral	1.680 g
Injection	Parenteral	50 mg/2mL
Tablet	Oral	400 mg
Syrup	Oral	1.500 mg
Granule, for solution	Oral	150 MG
Syrup		150 MG/10ML
Tablet	Oral	100 MG
Tablet, film coated	Oral	167412 MG
Solution	Parenteral	50.000 mg
Tablet	Oral	300.00 mg
Tablet	Oral	75.000 mg
Tablet, film coated	Oral
Tablet, coated	Oral	150 mg
Tablet, delayed release	Oral	300 mg
Tablet, coated	Oral	334.88 mg
Tablet, coated	Oral	33488000 mg
Solution	Intravenous	50 mg
Injection, solution	Intravenous	50 MG/5ML
Tablet, coated	Oral	300 mg
Tablet	Oral	150 MG
Tablet	Oral	300 MG
Tablet, film coated	Oral	75 MG
Solution	Intramuscular; Intravenous	50 mg
Injection	Intramuscular; Intravenous	25 mg/1mL
Solution	Oral	15 mg/1mL
Solution	Oral	15.0 mg/1mL
Solution	Oral	150 mg/1mL
Syrup	Oral	15 mg/1mL
Syrup	Topical	15 mg/1mL
Tablet, coated	Oral	150 mg/1
Tablet, coated	Oral	75 mg/1
Tablet, film coated	Oral	150 mg/1
Tablet, film coated	Oral	300 mg/1
Injection		25 mg/ml
Injection	Intramuscular; Intravenous	27.9 mg
Injection	Intramuscular; Intravenous	28.6 mg
Tablet, film coated	Oral	167.4 MG
Tablet, film coated	Oral	168 mg
Capsule	Oral	150 mg/1
Capsule	Oral	300 mg/1
Injection		28 mg
Powder	Not applicable	1 g/1g
Solution	Oral	150 mg/10mL
Solution	Oral	75 mg/5mL
Tablet	Oral	150 mg/1
Tablet	Oral	300 mg/1
Tablet, film coated	Oral	75 mg/1
Syrup	Oral	15 MG/ML
Tablet, coated	Oral
Tablet	Oral
Injection	Intramuscular; Intravenous	29.3 mg/ml
Syrup	Oral	1.50 g
Tablet, coated	Oral	15000000 mg
Syrup	Oral	75 MG/5ML
Tablet	Oral	75 mg
Kit	Oral
Solution		50.000 mg
Tablet	Oral	150.00 mg
Syrup	Oral	1.500 g
Solution	Intramuscular; Intravenous	25 mg / mL
Solution	Oral	75 mg / 5 mL
Injection	Intramuscular; Intravenous	25 mg/2ml
Injection, solution
Tablet, soluble	Oral
Injection	Intramuscular; Intravenous	25 mg
Tablet, delayed release	Oral	150 mg
Granule, for solution	Oral
Injection, solution	Intravenous
Syrup
Tablet	Oral
Solution	Intramuscular; Intravenous	25 mg/ml
Solution	Intramuscular; Intravenous
Tablet, coated	Oral	167.4 mg
Solution	Intramuscular	50.00 mg
Injection	Parenteral	50 mg
Tablet, effervescent	Oral
Concentrate	Intravenous
Injection, solution	Intramuscular; Intravenous	50 mg/2ml
Solution	Parenteral	50 mg
Injection	Intramuscular; Intravenous
Injection, solution	Intramuscular; Intravenous	25 mg/1mL
Injection, solution	Intravenous	50 mg/50mL
Liquid	Intramuscular; Intravenous	25 mg / mL
Solution	Intramuscular; Intravenous	50 mg / 2 mL
Tablet	Oral	84 mg/1
Tablet, effervescent	Oral	25 mg/1
Tablet, effervescent	Oral	168 mg
Tablet, effervescent	Oral	150 mg/1
Injection	Intramuscular; Intravenous	25 mg/ml
Solution	Oral	15 mg / mL
Syrup		150 ml
Syrup	Oral	150 mg/10ml
Tablet	Oral	150 mg / tab
Tablet	Oral	300 mg / tab
Capsule	Oral	150 mg / cap
Capsule	Oral	300 mg / cap
Injection, solution		25 mg/1ml
Tablet, film coated	Oral	150 mg
Tablet, film coated	Oral	300 mg
Solution		25 mg/1ml

Prices

Unit description	Cost	Unit
Zantac 300 mg tablet	7.96USD	tablet
Ranitidine hcl powder	5.2USD	g
Zantac EFFERdose 25 mg Effervescent Tabs	4.18USD	tab
Zantac 25 efferdose tablet	4.02USD	tablet
Zantac 150 mg tablet	3.11USD	tablet
Ranitidine HCl 300 mg capsule	2.85USD	capsule
Ranitidine HCl 300 mg tablet	2.79USD	tablet
Ranitidine 300 mg tablet	2.69USD	tablet
Ranitidine hcl 25 mg/ml vial	2.0USD	ml
Zantac 25 mg/ml vial	2.0USD	ml
Ranitidine HCl 150 mg capsule	1.58USD	capsule
Zantac 25 mg/ml	1.58USD	ml
Ranitidine HCl 150 mg tablet	1.54USD	tablet
Ranitidine 150 mg tablet	1.48USD	tablet
Ranitidine 25 mg/ml	1.26USD	ml
Ranitidine HCl 15 mg/ml Syrup	1.0USD	ml
Ratio-Ranitidine 300 mg Tablet	0.82USD	tablet
Apo-Ranitidine 300 mg Tablet	0.82USD	tablet
Co Ranitidine 300 mg Tablet	0.82USD	tablet
Mylan-Ranitidine 300 mg Tablet	0.82USD	tablet
Nu-Ranit 300 mg Tablet	0.82USD	tablet
Pms-Ranitidine 300 mg Tablet	0.82USD	tablet
Ran-Ranitidine 300 mg Tablet	0.82USD	tablet
Zantac 15 mg/ml Syrup	0.81USD	ml
Zantac 75 tablet	0.49USD	tablet
Apo-Ranitidine 150 mg Tablet	0.42USD	tablet
Co Ranitidine 150 mg Tablet	0.42USD	tablet
Mylan-Ranitidine 150 mg Tablet	0.42USD	tablet
Nu-Ranit 150 mg Tablet	0.42USD	tablet
Pms-Ranitidine 150 mg Tablet	0.42USD	tablet
Ran-Ranitidine 150 mg Tablet	0.42USD	tablet
Ratio-Ranitidine 150 mg Tablet	0.42USD	tablet
Novo-Ranidine 300 mg Tablet	0.38USD	tablet
Phl-Ranitidine 300 mg Tablet	0.38USD	tablet
Sandoz Ranitidine 300 mg Tablet	0.38USD	tablet
Zantac 300 mg Tablet	0.38USD	tablet
Zantac 75 mg tablet	0.28USD	tablet
Wal-zan 75 mg tablet	0.27USD	tablet
Zantac 15 mg/ml Solution	0.23USD	ml
Ranitidine hcl 75 mg tablet	0.22USD	tablet
Sm acid reducer 75 mg tablet	0.22USD	tablet
Acid reducer 150 mg tablet	0.2USD	tablet
Wal-zan 75 tablet	0.2USD	tablet
Novo-Ranidine 150 mg Tablet	0.19USD	tablet
Phl-Ranitidine 150 mg Tablet	0.19USD	tablet
Sandoz Ranitidine 150 mg Tablet	0.19USD	tablet
Zantac 150 mg Tablet	0.19USD	tablet
CVS Pharmacy ranitidine 75 mg tablet	0.15USD	tablet
Apo-Ranitidine 15 mg/ml Solution	0.12USD	ml
Novo-Ranidine 15 mg/ml Solution	0.12USD	ml
Acid reducer 75 mg tablet	0.11USD	tablet
CVS Pharmacy acid reducer 75 mg tablet	0.11USD	tablet
Qc ranitidine 75 mg tablet	0.07USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)	Region
US5098715	No	1992-03-24	2010-12-20
US5102665	No	1992-04-07	2009-12-23
CA1332610	No	1994-10-18	2011-10-18

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	134	https://www.chemicalbook.com/ChemicalProductProperty_US_CB3685534.aspx
water solubility	soluble in water	https://www.chemicalbook.com/ChemicalProductProperty_US_CB3685534.aspx
logP	0.2	https://www.fip.org/files/fip/BPS/BCS/Monographs/Ranitidine_Hydrochloride.pdf
Caco2 permeability	0.49	https://www.ncbi.nlm.nih.gov/pubmed/9755906
pKa	8.2 and 2.7	https://www.fip.org/files/fip/BPS/BCS/Monographs/Ranitidine_Hydrochloride.pdf

Predicted Properties

Property	Value	Source
Water Solubility	0.0795 mg/mL	ALOGPS
logP	0.79	ALOGPS
logP	0.99	Chemaxon
logS	-3.6	ALOGPS
pKa (Strongest Basic)	7.8	Chemaxon
Physiological Charge	1	Chemaxon
Hydrogen Acceptor Count	5	Chemaxon
Hydrogen Donor Count	2	Chemaxon
Polar Surface Area	83.58 Å2	Chemaxon
Rotatable Bond Count	10	Chemaxon
Refractivity	94.15 m3·mol-1	Chemaxon
Polarizability	33.78 Å3	Chemaxon
Number of Rings	1	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	0.9936
Blood Brain Barrier	-	0.8783
Caco-2 permeable	-	0.5838
P-glycoprotein substrate	Substrate	0.8527
P-glycoprotein inhibitor I	Non-inhibitor	0.8782
P-glycoprotein inhibitor II	Non-inhibitor	0.8893
Renal organic cation transporter	Non-inhibitor	0.8177
CYP450 2C9 substrate	Non-substrate	0.7702
CYP450 2D6 substrate	Substrate	0.7414
CYP450 3A4 substrate	Non-substrate	0.5565
CYP450 1A2 substrate	Non-inhibitor	0.9046
CYP450 2C9 inhibitor	Non-inhibitor	0.9071
CYP450 2D6 inhibitor	Non-inhibitor	0.923
CYP450 2C19 inhibitor	Non-inhibitor	0.9025
CYP450 3A4 inhibitor	Non-inhibitor	0.8308
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.7819
Ames test	Non AMES toxic	0.9132
Carcinogenicity	Non-carcinogens	0.8077
Biodegradation	Not ready biodegradable	0.9249
Rat acute toxicity	2.0903 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Strong inhibitor	0.8628
hERG inhibition (predictor II)	Non-inhibitor	0.8734

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted 1H NMR Spectrum	1D NMR	Not Applicable
Predicted 13C NMR Spectrum	1D NMR	Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å2)	Source type	Source
[M-H]-	166.67119	predicted	DeepCCS 1.0 (2019)
[M+H]+	169.02922	predicted	DeepCCS 1.0 (2019)
[M+Na]+	175.12248	predicted	DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Binding Properties

×

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	3400	N/A	N/A	A29166

Details

Binding Properties1. Histamine H2 receptor

Kind

Protein

Organism

Humans

Pharmacological action

Yes

Actions

Antagonist

General Function

The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) signaling pathway (By similarity)

Specific Function

G protein-coupled serotonin receptor activity

Gene Name

HRH2

Uniprot ID

P25021

Uniprot Name

Histamine H2 receptor

Molecular Weight

40097.65 Da

References

1. Pattichis K, Louca LL: Histamine, histamine H2-receptor antagonists, gastric acid secretion and ulcers: an overview. Drug Metabol Drug Interact. 1995;12(1):1-36. [Article]
2. Grant SM, Langtry HD, Brogden RN: Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1989 Jun;37(6):801-70. doi: 10.2165/00003495-198937060-00003. [Article]
3. Rubinstein R, Nissenkorn I, Cohen S: Acetylcholine mediation of the contractile response to histamine in human bladder detrusor muscle. Eur J Pharmacol. 1987 Oct 6;142(1):45-50. doi: 10.1016/0014-2999(87)90652-2. [Article]
4. Doenicke A, Moss J, Lorenz W, Hoernecke R, Gottardis M: Are hypotension and rash after atracurium really caused by histamine release? Anesth Analg. 1994 May;78(5):967-72. doi: 10.1213/00000539-199405000-00023. [Article]
5. Kirch W, Hutt HJ, Heidemann H, Ramsch K, Janisch HD, Ohnhaus EE: Drug interactions with nitrendipine. J Cardiovasc Pharmacol. 1984;6 Suppl 7:S982-5. [Article]
6. Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
7. FDA Approved Drug Products: ZANTAC (ranitidine hydrochloride) injection [Link]

Binding Properties

×

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	2300	N/A	N/A	A27967
IC 50 (nM)	650	N/A	N/A	A29167

Details

Binding Properties2. Acetylcholinesterase

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

Actions

Inhibitor

Curator comments

The FDA label indicates that ranitidine is not an anticholinergic agent, likely because its weak anticholinergic effects observed in studies do not result in clinical effects.

General Function

Hydrolyzes rapidly the acetylcholine neurotransmitter released into the synaptic cleft allowing to terminate the signal transduction at the neuromuscular junction. Role in neuronal apoptosis

Specific Function

acetylcholine binding

Gene Name

ACHE

Uniprot ID

P22303

Uniprot Name

Acetylcholinesterase

Molecular Weight

67795.525 Da

References

1. Petroianu GA, Arafat K, Schmitt A, Hasan MY: Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of ranitidine. J Appl Toxicol. 2005 Jan-Feb;25(1):60-7. doi: 10.1002/jat.1036. [Article]
2. Kounenis G, Koutsoviti-Papadopoulou M, Elezoglou V: The inhibition of acetylcholinesterase by ranitidine: a study on the guinea pig ileum. J Pharmacobiodyn. 1986 Nov;9(11):941-5. [Article]
3. Aono M, Moriga M, Mizuta K, Narusawa H: Cholinergic effects of histamine-H2 receptor antagonists partly through inhibition of acetylcholinesterase. Gastroenterol Jpn. 1986 Jun;21(3):213-9. doi: 10.1007/bf02774563. [Article]
4. Laine-Cessac P, Turcant A, Premel-Cabic A, Boyer J, Allain P: Inhibition of cholinesterases by histamine 2 receptor antagonist drugs. Res Commun Chem Pathol Pharmacol. 1993 Feb;79(2):185-93. [Article]
5. FDA Approved Drug Products: ZANTAC (ranitidine hydrochloride) injection [Link]

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at June 13, 2005 13:24 / Updated at October 21, 2024 12:55